ImmunityBio, Inc. or Geron Corporation: Who Manages SG&A Costs Better?

SG&A Cost Management: ImmunityBio vs. Geron Corporation

In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, ImmunityBio, Inc. and Geron Corporation have shown contrasting approaches to SG&A cost management. ImmunityBio's SG&A expenses have surged by approximately 2,900% from 2014 to 2023, reflecting its aggressive growth strategy. In contrast, Geron Corporation has maintained a more conservative increase of around 310% over the same period.

While ImmunityBio's higher expenses might indicate rapid expansion and investment in innovation, Geron's steadier approach suggests a focus on sustainable growth. Investors and stakeholders should consider these trends when evaluating the companies' financial strategies. The data highlights the importance of balancing cost management with growth ambitions in the biotech sector.